Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TSLP

TSLP

Brief Information

Name:Thymic stromal lymphopoietin
Target Synonym:Thymic stromal lymphopoietin,TSLP
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

TSP-H52Ha-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Human TSLP (R127A, R130A), His Tag (Cat. No. TSP-H52Ha) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 4.22 nM as determined in SPR assay (Biacore T200) (Routinely tested).

TSP-H52Hb-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Human TSLP, His Tag (Cat. No. TSP-H52Hb) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 1.81 nM as determined in SPR assay (Biacore T200) (Routinely tested).

Synonym Name

TSLP

Background

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine involved in the pathology of inflammatory skin diseases, and is widely expressed by epithelial cells. Human TSLP cDNA encodes a 159 amino acid (aa) residue precursor protein with a 28 aa signal sequence (4, 5). Human TSLP has been shown to developing nondeletional central tolerance, amplifying epithelium-induced class switching, inducing atopic diseases and maintaining intestinal noninflammatory environment. Among diverse cells responding to Human TSLP, CD11c+ dendritic cells are the most obviously characterized target cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tezepelumab MEDI-9929; AMG-157 Approved Amgen Inc Tezspire United States Asthma Astrazeneca Ab 2021-12-17 Lung Diseases, Obstructive; Nasal Polyps; Chronic Urticaria; Nose Diseases; Lung Diseases; Sinusitis; Asthma; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic; Hypersensitivity Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BSI-045B BSI-045B Phase 1 Clinical Boaoxin Biotechnology(Nanjing) Co Ltd Dermatitis, Atopic Details
SHR-1905 SHR-1905 Phase 1 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Asthma Details
GR-1802 GR-1802 Phase 2 Clinical Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd Asthma; Sinusitis; Dermatitis, Atopic Details
CSJ-117 CSJ-117; NOV-14 Phase 2 Clinical Novartis Pharma Ag Asthma; Pulmonary Disease, Chronic Obstructive Details
CM-326(Connaught Biomedical Technology) CM-326 Phase 2 Clinical Keymed Biosciences Co Ltd Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message